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The Notch signaling pathway is a con-
served intercellular signaling mecha-
nism, and mutations in Notch pathway
components disrupt embryonic develop-
ment in diverse organisms and cause
inherited disease syndromes in humans
(reviewed in Artavanis-Tsakonas et al.,
1999; Gridley, 2003). Genes of
the Notch family (NOTCH1-
NOTCH4 in mammals) encode
single-pass transmembrane
receptors that bind to trans-
membrane ligands encoded
by genes of the Delta and
Jagged/Serrate families.
NOTCH family proteins are
proteolytically processed both
during transit to the cell sur-
face and upon ligand binding.
In mammals, NOTCH precur-
sors (for example, NOTCH1) in
the secretory pathway are
cleaved in the extracellular
domain by a furin-type pro-
tease. This results in formation





the signal peptide and 36
tandemly repeated copies of
an epidermal growth factor-like
motif. The transmembrane
subunit contains a short extra-
cellular domain, the mem-
brane-spanning region, and an
intracellular domain (termed
ICN1) containing several con-
served motifs. Stable association of the
two NOTCH1 subunits is dependent on a
newly described heterodimerization
domain comprising the carboxy-terminal
end of the extracellular subunit and the
extracellular amino-terminal end of 
the transmembrane subunit (Sanchez-
Irizarry et al., 2004). Upon interaction
with a ligand-expressing cell, additional
proteolytic cleavages occur that result in
receptor activation and signal transduc-
tion. The final cleavage, which occurs
within the plasma membrane and releas-
es ICN1 into the cytosol, is catalyzed 
by the γ-secretase complex. Once
released, ICN1 translocates to the
nucleus, where it participates in the for-
mation of a large transcriptional com-
plex that activates NOTCH target gene
transcription.
It has been known for more than a
decade that disregulated expression of
the intracellular domains of Notch family
receptors contributes to the formation of
several cancers in mammals (reviewed
in Radtke and Raj, 2003; Zweidler-
McKay and Pear, 2004). The human
NOTCH1 gene, the first mammalian
Notch homolog isolated, was identified
through the cloning of a t(7;9) chromoso-
mal translocation found in a subset of
human T-ALL (Ellisen et al., 1991). This
translocation brings the disrupted
NOTCH1 gene under the transcriptional
control of the T cell receptor β locus and
results in the disregulated expression of
intracellular forms of the NOTCH1 pro-
tein that resemble ICN1. Work in mouse
models revealed that ICN1 expression in
bone marrow resulted in T cell leukemia
in 100% of the transplanted
mice (Zweidler-McKay and
Pear, 2004). However, despite
the efficacy of ICN1 expres-
sion in inducing T cell
leukemia in mouse models, it
was puzzling that the t(7;9)
translocation was present in
less than 1% of human T-ALL
tumors.
A recent paper by Weng
and colleagues now provides
an explanation for this enigma
(Weng et al., 2004). These
authors had shown previously
that sustained NOTCH1 sig-
naling was required for prolif-
eration and survival of a T-ALL
cell line containing the t(7;9)
translocation. In the new
study, Weng et al. assessed
whether growth of other T-ALL
cell lines lacking the t(7;9)
translocation was sensitive to
growth arrest induced by inhi-
bition of γ-secretase activity.
They found that several T-ALL
cell lines exhibited G0/G1 cell
cycle arrest when cultured in
the presence of a γ-secretase
inhibitor.They then sequenced
the NOTCH1 gene in these
cell lines and found mutations in
sequences encoding two different
domains of the NOTCH1 protein in four
of the five cell lines that exhibited γ-sec-
retase-dependent proliferation. They
observed missense mutations of con-
served amino acid residues in the het-
erodimerization domain of the NOTCH1
protein and frameshift mutations that led
to truncation of the PEST domain (a
motif implicated in the regulation of pro-
tein turnover) at the carboxy terminus of
the NOTCH1 protein. Importantly, both
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While the human NOTCH1 gene initially was cloned as part of a translocation breakpoint in T cell acute lymphoblastic
leukemia (T-ALL) tumors, this translocation is present in only a small percentage of T-ALL patients. A recent paper by Weng
et al. (2004) demonstrates that novel types of activating mutations in the NOTCH1 gene occur in more than half of all T-ALL
cases, implicating NOTCH1 as a major player in the etiology of T-ALL.
Figure 1. Model for NOTCH1 activation by heterodimerization domain
and PEST domain mutations
In the wild-type NOTCH1 protein (right), stable association of the furin-
cleaved extracellular and transmembrane subunits requires the het-
erodimerization domain. Upon interaction with a NOTCH
ligand-expressing cell, two additional proteolytic cleavages occur in
the NOTCH1 protein. The final cleavage, catalyzed by γ-secretase,
releases the NOTCH1 intracellular domain (ICN1), which can then
translocate to the nucleus. In the mutant NOTCH1 protein (left), Weng
et al. (2004) propose that heterodimerization domain missense muta-
tions (red X) increase levels of ICN1 by enhancing γ-secretase cleav-
age, while the PEST domain truncations increase ICN1 half-life.
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types of mutation were present in cis in
the same NOTCH1 allele in all four cell
lines.
Weng et al. then examined primary T-
ALL tumors for the presence of NOTCH1
mutations and frequently found muta-
tions in the same two domains. At least
one mutation was identified in more than
50% of T-ALL bone marrow samples,
which included representatives of all
major molecular subtypes of T-ALL
(Ferrando et al. 2002). To prove that
these mutations activated NOTCH1
function, Weng et al. performed tran-
scriptional reporter assays with NOTCH-
sensitive reporters.They found activation
of transcriptional activity in both single
heterodimerization domain mutations (3-
to 9-fold increase in activity) and PEST
domain mutations (1.5- to 2-fold
increase). Interestingly, combining these
two types of mutation in cis in the same
NOTCH1 allele led to striking synergy of
transcriptional activation, resulting in a
20- to 40-fold increase in activity.
Transcriptional stimulatory effects of
these mutant NOTCH1 proteins were
completely abrogated by culturing trans-
fected cells with a γ-secretase inhibitor.
These mutations represent a novel
means to activate Notch signaling func-
tion. While the mechanistic details are
currently unknown, Weng et al. propose
a model for the synergy of the two types
of mutations (Figure 1). They suggest
that the heterodimerization domain
mutations increase the rate of production
of ICN1 by enhancing γ-secretase cleav-
age, while the PEST domain truncations
increase ICN1 half-life. These predic-
tions remain to be verified experimental-
ly. These results help explain the
contradiction between the efficacy of T
cell leukemia induction by activating
NOTCH1 function in mouse models and
the rare occurrence of the t(7;9) translo-
cation in human T-ALL tumors. The t(7;9)
translocation can occur only in the small
subset of committed T cell progenitors
undergoing V-D-J recombination at the T
cell receptor β locus, while the NOTCH1
missense and frameshift mutations could
occur at many additional stages of T cell
development, including the hemato-
poietic stem cell or the common
lymphoid progenitor.
These new findings also have thera-
peutic implications. Under currently uti-
lized therapeutic regimens, the 5 year
survival rate for pediatric and adolescent
T-ALL patients is approximately
60%–75% (Ferrando et al., 2002). Since
both transcriptional activation and cell
proliferation caused by the NOTCH1
heterodimerization and PEST domain
mutations are dependent on γ-secre-
tase-mediated proteolytic cleavage, γ-
secretase is a potential therapeutic
target in cases of T-ALL refractory to cur-
rent therapeutic approaches. Small mol-
ecule γ-secretase inhibitors are being
intensively studied as therapeutics for
Alzheimer’s disease (reviewed in Wolfe,
2002). However, potential side effects of
γ-secretase inhibitors, due to their inhibi-
tion of Notch signaling activity, remain a
concern. A recent study showed that
administration of a γ-secretase inhibitor
to mice had deleterious effects on the
lymphoid and intestinal systems (Wong
et al., 2004). Furthermore, mice with a
reduction in gene dosage of the two pre-
senilin genes (Psen1+/− Psen2−/− double
mutant mice), which encode compo-
nents of the γ-secretase complex, devel-
op an age-dependent myeloproliferative
disease (Qyang et al., 2004). These
results suggest that caution may be
required when introducing γ-secretase
inhibitors into the clinical arena.
Nevertheless, the findings of Weng et al.
transform the role of NOTCH1 activation
in the etiology of T-ALL from bit player to
star and raise hopes for novel therapeu-
tic approaches to this disease.
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